Volume 13, Issue 4 (9-2023)                   JABS 2023, 13(4): 265-270 | Back to browse issues page

Ethics code: 0


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Maghbool M, Samizadeh B. Concordance of HER2 Status between Core Needle Biopsy and Surgical Resected Specimens of Breast Cancer: A Narrative Review. JABS 2023; 13 (4) :265-270
URL: http://jabs.fums.ac.ir/article-1-3006-en.html
1- Department of Pathology, Clinical Research Development Unit of Valiasr Hospital, Fasa University of Medical Sciences, Fasa, Iran
2- Department of Pathology, Clinical Research Development Unit of Valiasr Hospital, Fasa University of Medical Sciences, Fasa, Iran , bsamizadeh8@gmail.com
Abstract:   (671 Views)
Background & Objective: HER2, a molecular biomarker, is routinely evaluated in breast cancer patients to guide therapeutic decisions. However, the concordance of HER2 status between core-needle biopsy (CNB) and surgical specimen (SS) samples is not always high, potentially affecting the accuracy of diagnosis and treatment. This study aims to review recent studies assessing the agreement of HER2 status between CNB and SS samples in breast cancer patients.
Materials & Methods: A literature search was conducted in PubMed, Scopus, and Google Scholar databases from January 2018 to August 2023 using the keywords: concordance, core needle biopsy, resection, HER2 status. Ten articles meeting the inclusion criteria were selected for this review.
Results: The results demonstrated variable concordance rates of HER2 status between CNB and SS samples, ranging from 83.3% to 99.5%. The primary factors influencing discordance were tumor heterogeneity, preoperative treatment, sampling error, and differing testing methods. Discordance was more prevalent in HER2-negative and HER2-low tumors compared to HER2-positive tumors.
Conclusion: The concordance of HER2 status between CNB and SS samples is generally high but not perfect. Therefore, retesting HER2 status on SS samples is recommended to ensure optimal treatment decisions for breast cancer patients.
 
Full-Text [PDF 586 kb]   (130 Downloads)    
Type of Study: Review | Subject: Pathology
Received: 2023/09/29 | Accepted: 2023/11/6 | Published: 2024/01/28

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advanced Biomedical Sciences

Designed & Developed by: Yektaweb

Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)